SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001628280-23-029352
Filing Date
2023-08-14
Accepted
2023-08-14 16:09:34
Documents
14
Period of Report
2023-08-14
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K eigr-20230814.htm   iXBRL 8-K 27532
5 EX-99.1 eigr-2023_augustx14xexx991.htm EX-99.1 101864
6 image.jpg GRAPHIC 28424
  Complete submission text file 0001628280-23-029352.txt   293343

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT eigr-20230814.xsd EX-101.SCH 1904
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT eigr-20230814_lab.xml EX-101.LAB 23834
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT eigr-20230814_pre.xml EX-101.PRE 12510
8 EXTRACTED XBRL INSTANCE DOCUMENT eigr-20230814_htm.xml XML 2710
Mailing Address 2155 PARK BOULEVARD PALO ALTO CA 94306
Business Address 2155 PARK BOULEVARD PALO ALTO CA 94306 650-279-9845
Eiger BioPharmaceuticals, Inc. (Filer) CIK: 0001305253 (see all company filings)

IRS No.: 361004130 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36183 | Film No.: 231170091
SIC: 2836 Biological Products, (No Diagnostic Substances)